Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Biomaterials. 2015 Dec 29;82:94–112. doi: 10.1016/j.biomaterials.2015.12.025

Fig. 3.

Fig. 3

Fate of angiogenesis induced by combination or single protein therapies. A combination therapy that employs proteins involved in triggering angiogenesis (i.e. VEGF, FGF-2) in combination with proteins involved in stabilizing new blood vessels by pericytes (i.e. PDGF, ANG1), is more likely to induce a robust angiogenesis process forming mature and stable vasculature. Single protein therapies might lead to a transient angiogenesis process with new blood vessels prone to regression due to lack of stability and maturity provided by pericytes.